
Abstract Background Autoimmune blistering diseases are rare chronic disorders caused by autoantibodies targeting structural proteins in the skin and mucous membranes. These diseases can severely affect patients’ psychological wellbeing. Objectives This study aimed to evaluate the psychosocial burden in newly diagnosed patients with pemphigus and pemphigoid, focusing on anxiety, depression, post-traumatic stress disorder (PTSD), suicide risk and quality of life. Methods Fifty patients (29 with pemphigus, 21 with pemphigoid), diagnosed between October 2023 and October 2024 at the Blistering Diseases Unit, Department of Dermatology and Venereology, were included. Data included sociodemographic information, disease severity [Pemphigus Disease Area Index (PDAI) and Bullous Pemphigoid Disease Area Index], and psychosocial assessments using Skindex-16 (quality of life), Hospital Anxiety and Depression Scale, Post-Traumatic Stress Disorder Checklist for for Diagnostic and Statistical Manual of Mental Disorders, 5th edition, and Suicide Probability Scale. Analysis was performed using IBM SPSS version 26.0. Results Diagnoses included pemphigus vulgaris (52%), bullous pemphigoid (36%), pemphigus foliaceus (6%), mucous membrane pemphigoid (4%) and gestational pemphigoid (2%). Mean disease severity scores were 26.10 ± 15.83 for pemphigus and 37.86 ± 28.53 for pemphigoid. Higher PDAI scores were associated with worse symptom-related quality of life (Skindex-16 Symptoms; P = 0.049). In patients with pemphigus, anxiety severity was strongly associated with higher PTSD symptom scores (P < 0.001), and depression was linked to increased hopelessness (P = 0.014). In patients with pemphigoid, suicide risk scores were significantly elevated (P < 0.001), and depression was associated with greater emotional distress (P = 0.030) and suicidal ideation (P = 0.025). PTSD symptoms were associated with increased anxiety and impaired quality of life in both groups. PTSD severity independently predicted poorer quality of life (pemphigus: P < 0.001; pemphigoid: P = 0.004), and increased suicide risk in patients with pemphigoid (P = 0.005). Conclusions Patients with autoimmune blistering diseases experience high psychological burden. Integrating psychiatric evaluation into routine care is essential for improving outcomes.
Topical corticosteroids (TCS) are central to the management of atopic dermatitis, but patient concerns and a lack of clear quantitative guidance may contribute to its undertreatment. In an international survey of International Society of Atopic Dermatitis (ISAD) members, most dermatologists reported using twice-weekly proactive therapy, with lower potencies in children and moderate-potency regimens in adolescents and adults, but there was substantial variability in prescribed quantities and limited provision of explicit dosing instructions. These findings highlight a gap between therapeutic concepts and practice, supporting the need for simple, age-adapted dosing frameworks to improve communication, adherence and confidence in long-term TCS use.
Frimpong-Manso et al. provide useful qualitative insight into pressures affecting UK dermatology trainees, but their 44% burnout figure reflects above-median emotional exhaustion within the sample rather than prevalence based on an independently established threshold. This distinction matters as the result is compared with international estimates and the findings are presented as a baseline for policy and research. Reporting inconsistencies and the claim of independence from demographic factors also require clarification.
Patients with chronic spontaneous urticaria (CSU) experience substantial delays before specialist assessment, with a mean time from symptom onset to review of 46 months – far exceeding the 6-week National Institute for Health and Care Excellence (NICE) referral benchmark. In this tertiary care cohort, over one-third of patients had severe clinical disease and more than a quarter were experiencing a severe psychosocial impact at presentation, with clinical and psychosocial severity strongly correlated. Patients with milder cases of CSU appeared to remain in primary care for prolonged periods without escalation, and psychosocial assessment was inconsistent across the referral pathway. These findings highlight the need for earlier primary care optimization, stronger adherence to NICE guidance and integrated psychosocial assessment to reduce disease burden and improve outcomes.
Abstract The gut–skin axis represents a bidirectional network linking intestinal and cutaneous microbial communities with host immune signalling, metabolic activity and epithelial barrier function. Disruption of this system (dysbiosis) has been implicated in the pathogenesis of inflammatory dermatological conditions, including atopic dermatitis, psoriasis, acne vulgaris, hidradenitis suppurativa and chronic wounds. This review focuses on contemporary strategies aimed at normalizing dysbiosis rather than broadly suppressing inflammation or microbial communities. Recent studies (2022–26) suggest that immune-targeted therapies and microbiome-directed interventions exert secondary effects on microbial composition, diversity and function. Biologic agents and small-molecule inhibitors, including interleukin (IL)-4Rɑ, IL-13, IL-17/23 and Janus kinase pathway inhibitors, are associated with partial restoration of microbial diversity and reductions in pathogenic taxa, particularly Staphylococcus aureus, alongside clinical improvement. There are parallel advances in microbiome-targeted therapeutics that offer complementary or alternative approaches. Live biotherapeutic products, such as Roseomonas mucosa, Staphylococcus hominis A9, ammonia-oxidizing bacteria and noninflammatory Cutibacterium acnes phylotypes, demonstrate strain-specific pathogen suppression, epithelial function enhancement and immunomodulatory effects without promoting antimicrobial resistance. Postbiotic and metabolite-based therapies replicate commensal signalling through delivery of short-chain fatty acids, indole derivatives and aryl hydrocarbon receptor agonists, offering regulatory feasibility and stability advantages over live organisms. Bacteriophage and recombinant endolysin therapies provide precision eradication of pathogenic strains while preserving commensal ecosystems, with early translational and clinical data supporting safety and efficacy. Lastly, gut-targeted interventions, including dietary modification, oral probiotics, prebiotics and faecal microbiota transplantation, highlight the systemic contribution of intestinal microbial homeostasis to skin inflammation. These strategies collectively signal a paradigm shift toward ecological restoration and immune recalibration. This review synthesizes recent evidence on the therapeutic modulation of the gut–skin axis, integrating mechanistic insights with emerging clinical applications.